Terms ending in 2037
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,877,042 | Anti-Hypusine Antibodies and Uses Thereof In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 12,099,064 | Anti-Hypusine Antibodies and Uses Thereof In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,692,043 | Peptidomimetic Compounds and Antibody-Drug Conjugates Thereof In force · High confidence | MedImmune Limited | In force | High confidence | |
| US 11,535,671 | Therapeutic and Diagnostic Methods for Cancer In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,337,852 | Therapeutic Agent Delivery Device In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,323,094 | Humanized and Affinity Matured Antibodies to FCRH5 and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| US 10,478,553 | Apparatus for Subretinal Administration of Therapeutic Agent via a Curved Needle In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,246,461 | Dosage Form Compositions Comprising an Inhibitor of Bruton's Tyrosine Kinase In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,365,197 | Dosage Form Compositions Comprising an Inhibitor of Bruton's Tyrosine Kinase In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,219,936 | Therapeutic Agent Delivery Device with Advanceable Cannula and Needle In force · High confidence | Genentech, Inc. | In force | High confidence | |
| 54 more term ends in 2037 · Pro | |||||
10 of 64 patents shown. Soonest term end first, then patent number.
Pro members see all 64.
59 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.